Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB2093 : II-18  update : 2022/01/11
CommentHuman cell line derived from lung cancer. Adenocarcinoma. TKG0177 (Deposited from Tohoku Univ.).
Comment from the depositor
Terms and conditionsA prior written permission of the approver(Originator) is necessary for any kind of use including academic use and for-profit use.
Remarks
approver's address
×
English
Address
Japan Anti-Tuberculosis Association MIYAGI

2-3-1 Nakayamayoshinari, Aoba-ku, Sendai, Miyagi 989-3203 Japan
Dr.Kobayashi, Syunsuke
Fax. +81-22-719-5166
Order Form Order Form(C-0005.pdf)   Approval Form(C-0006.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Obinata, Masuo
Originator Kobayashi, Syunsuke
Year of deposit 2005
Original cell TKG0177
Animal _human < Mammals
Genus homo
Species sapiens
Tissue lung
Disease name adenocarcinoma
Classification cancer
History Cell Resource Center for Biomedical Research, Tohoku University(TKG0177)
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_6659
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.25% trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : once/week, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
STR(human) OK
Images
deposit info
lot info
Reference information Reference 1
User's Publication 12


To topTop
Reference
3447      Kokenshi  1990  42:73-79 

To topTop
User's Publication
20501  Yasuda Y, Nagano T, Jimbo N, Kiriu T, Suraya R, Hazama D, Yamamoto M, Maniwa Y, Nishimura Y, Kobayashi K.  Chloride Intracellular Channel 1 Expression Is Associated With Poor Prognosis of Lung Adenocarcinoma.  Anticancer Res  2022  42(1):271-277  PubMed ID: 34969734
20304  Nakasone S, Suzuki A, Okazaki H, Onodera K, Zenkoh J, Ishii G, Suzuki Y, Tsuboi M, Tsuchihara K.  Predictive markers based on transcriptome modules for vinorelbine-based adjuvant chemotherapy for lung adenocarcinoma patients.  Lung Cancer  2021  158:115-125  PubMed ID: 34157583
13215  Miwa N, Nagano T, Jimbo N, Dokuni R, Kiriu T, Mimura C, Yasuda Y, Katsurada M, Yamamoto M, Tachihara M, Tanaka Y, Kobayashi K, Itoh T, Maniwa Y, Nishimura Y.  Caspase Recruitment Domain-Containing Protein 9 Expression is a Novel Prognostic Factor for Lung Adenocarcinoma.  Onco Targets Ther  2020    PubMed ID: 32982291
14832  Saito S, Kitamura-Muramatsu Y, Komine F, Polat M, Takeshima SN, Takei M, Aida Y.  Absence of bovine leukemia virus proviral DNA in Japanese human blood cell lines and human cancer cell lines  Arch Virol  2020  165(1):207-214  PubMed ID: 31776677
4872  Tanaka H, Sakagami H, Kaneko N, Konagai S, Yamamoto H, Matsuya T, Yuri M, Yamanaka Y, Mori M, Takeuchi M, Koshio H, Hirano M, Kuromitsu S.  Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.  Mol Cancer Ther  2019  18(8):1366-1373  PubMed ID: 31092564
11040  Koh Furugaki, Marie Mochizuki, Mirei Kohno, Sei Shu, Naoki Harada, Yasushi Yoshimura   Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion  BMC Cancer  2019  19(1):301  PubMed ID: 30943926
10768  Kashima Y, Suzuki A, Liu Y, Hosokawa M, Matsunaga H, Shirai M, Arikawa K, Sugano S, Kohno T, Takeyama H, Tsuchihara K, Suzuki Y.  Combinatory use of distinct single-cell RNA-seq analytical platforms reveals the heterogeneous transcriptome response.  Sci Rep  2018  8:3482  PubMed ID: 29472726
10411  Kunimasa K, Nagano T, Shimono Y, Dokuni R, Kiriu T, Tokunaga S, Tamura D, Yamamoto M, Tachihara M, Kobayashi K, Satouchi M, Nishimura Y.  Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.  Cancer Sci.  2017  108:1368-1377  PubMed ID: 28445002
12672  Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Watanabe S, Ichikawa H, Yamamoto N, Kuwano K, Ohe Y.  Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors  Oncologist  2016  21(2):156-64  PubMed ID: 26768482
14941  Ofuji K, Tada Y, Yoshikawa T, Shimomura M, Yoshimura M, Saito K, Nakamoto Y, Nakatsura T.  A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer  Int J Oncol  2015  46(2):497-504  PubMed ID: 25532027
8277  Shirogane Y, Takeda M, Tahara M, Ikegame S, Nakamura T, Yanagi Y.  Epithelial-mesenchymal transition abolishes the susceptibility of polarized epithelial cell lines to measles virus.  J. Biol. Chem.  2010  285:20882-90  PubMed ID: 20435897
6410  Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.  Is parainfluenza virus a threatening virus for human cancer cell lines?  Hum Cell  2009  22(3):81-4  PubMed ID: 19624309



Back Back Return Top Page